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Pulmonary disease (PD) due to nontuberculous mycobacteria (NTM) is increasing globally, but specific 
biomarkers for NTM-PD have not been established. As circulating miRNAs are promising biomarkers for 
various diseases, we investigated whether miRNAs have potential as NTM-PD biomarkers. Sera from 
12 NTM-PD patients due to Mycobacterium avium, M. intracellulare, M. abscessus, or M. massiliense 
and three healthy controls were initially evaluated via small RNA sequencing. Multiple miRNAs 
showed significant differences in expression in patients compared to in healthy controls, with some 
expression differences unique to PD caused by a specific mycobacterial species. Notably, 14 miRNAs 
exhibited significant expression differences in PD associated with all four mycobacteria. Validation 
by quantitative reverse-transcription-PCR in an additional 40 patients with NTM-PD and 40 healthy 
controls confirmed that four differentially expressed miRNAs (hsa-miR-484, hsa-miR-584-5p, hsa-miR-
625-3p, and hsa-miR-4732-5p) showed significantly higher serum expressions in NTM-PD patients 
than in controls. Receiver operating characteristic curve analysis of these four miRNAs supported 
the discriminative potential for NTM-PD and their combination provided an improved diagnostic 
value for NTM-PD. Furthermore, bioinformatics analysis revealed their 125 target genes, which were 
mostly associated with immune responses. Collectively, this study identified four miRNAs as potential 
biomarkers for NTM-PD and provided insight into NTM-PD pathophysiology.
Nontuberculous mycobacteria (NTM) are mycobacteria other than the Mycobacterium tuberculosis complex and 
Mycobacterium leprae. More than 180 officially recognized NTM species have been identified, with the most fre-
quent human pathogens associated with pulmonary disease (PD) due to NTM belonging to the Mycobacterium 
avium complex (MAC), followed by M. abscessus (MAB)1,2. MAC primarily comprises M. avium and M. intracel-
lulare, and MAB primarily comprises M. abscessus subspecies abscessus (hereafter referred to as M. abscessus) and 
M. abscessus subspecies massiliense (hereafter referred to as M. massiliense)1,2. Despite the global increase in the 
burden of NTM-PD in recent decades, there is limited information regarding specific biomarkers for distinguish-
ing patients with NTM-PD from healthy individuals or studies of the disease pathophysiology3,4.
MicroRNAs (miRNAs) are small, 18–25-nucleotide, endogenous, stable, highly conserved noncoding RNAs 
with important functions in post-transcriptional gene regulation under both physiological and pathological con-
ditions5,6. Numerous studies have reported the aberrant expression of several miRNAs in various conditions, 
including cancer and infectious diseases. miRNAs reportedly play an important regulatory role in the patho-
genesis or progression of infectious diseases7,8 and serve as potential modulators of innate and adaptive immune 
responses9,10. Serum miRNAs are not readily degraded by enzymes, unaffected by changes in temperature and 
time, and resistant to acids and alkalis11,12. Furthermore, serum miRNAs are stable, and evaluating serum miRNA 
profiles is a feasible diagnostic procedure in clinical laboratories. Because of their high diagnostic potential, 
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serum miRNAs have been evaluated as biomarkers in several pathological conditions including TB, with some 
studies achieving 82% to 100% accuracy in diagnosing TB by evaluating miRNA13–18. Additionally, several studies 
have reported differences in miRNA levels among patients with active TB, latent TB, and healthy controls18,19. 
Recently, the roles of miRNAs in mycobacterial infections, particularly in tuberculosis (TB), has received increas-
ing attention13,20–23 Such studies have reported that specific miRNAs are differentially expressed in macrophages 
or patients infected with M. tuberculosis complex and that several of these miRNAs interact with their cognate 
target genes. Additionally, studies have demonstrated that miRNAs are involved in the progression of TB and that 
serum miRNA profiles can be useful as potential diagnostic or therapeutic biomarkers in patients with TB13,20–23. 
The serum levels of miR-144 and miR-155, which were differentially expressed in patients with pulmonary TB 
compared to in healthy controls, have been reported to be diagnostic markers for TB24,25.
As the burden of NTM-PD is increasing worldwide, studies reporting on the expression of miRNA in 
NTM-PD have also increased. For example, overexpression of let-7e, miR-29a, and miR-886-5p inhibited M. 
avium-induced apoptosis in human monocyte-derived macrophages by modulating caspases 3 and 726. Serum 
miR-346, expressed in M. avium-infected macrophages secreted into the bloodstream, was quantitatively con-
trolled by bacterial load and identified as a potential biomarker of MAC-PD27. Although circulating miRNAs 
were recently recognized as promising disease biomarkers in infectious diseases, few studies have examined the 
role of miRNA in NTM-PD. Therefore, we evaluated serum miRNAs that are differentially expressed in NTM-PD 
patients compared to in healthy controls by RNA sequencing and explored the potency of serum miRNA expres-
sion profiles as discriminating markers for NTM-PD.
Results
patients. In total, 95 participants were recruited in this study, including 52 patients with NTM-PD and 43 
healthy volunteers (Table 1). The median age of the patients was 56 years, and 45 (87%) were female. The median 
body mass index of the 52 patients was 20.8 kg/m2, and 46 (89%) were never smokers. Among the patients with 
NTM-PD, the most common underlying respiratory disease was bronchiectasis (n = 48, 92%), followed by previ-
ous treated TB (n = 17, 33%). The median value of white blood cell count and erythrocyte sedimentation rate was 
6040/µL and 36 mm/hr, respectively. Out of the 52 patients with NTM-PD, 48 (92%) had nodular bronchiectatic 
form, and 4 (8%) had the fibrocavitary form (Supplementary Fig. S1). The median forced expiratory volume in 
1 second (%) on pulmonary function test at diagnosis was 79%. In the 43 healthy controls, the median age was 48 
years, and 29 (67%) patients were female.
Illumina-based small RNA sequencing of serum miRNAs. Serum levels of miRNA from 12 patients 
with NTM-PD, including patients infected with M. avium, M. intracellulare, M. abscessus, or M. massiliense (n = 3 
Characteristics NTM-PD (n = 52) Healthy Controls (n = 43)
Age (years) 56 (50–62) 48 (40–56)
Female sex 45 (87) 29 (67)
Body mass index (kg/m2) 20.8 (19.0–22.5) NA
Never smoker 46 (89) INA
Etiologic organism INA
M. avium 13 (25) —
M. intracellulare 14 (27) —
M. abscessus 13 (25) —
M. massiliense 12 (23) —
Underlying disease
Bronchiectasis 48 (92) —
Previously treated tuberculosis 17 (33) —
Previous thoracic surgery 1 (2) —
Chronic heart disease 1 (2) —
Chronic liver disease 1 (2) —
Laboratory data INA
White blood cell (/µL) 6040 (4780–7813) INA
Lymphocyte (%) 29.9 (19.5–34.6) INA
Erythrocyte sedimentation rate (mm/hr) 36 (18–52) INA
Albumin (g/dl) 4.5 (4.3–4.6) INA
Computed tomography finding —
Nodular bronchiectatic form 48 (92) —
Fibrocavitary form 4 (8) —
Positive acid fast stain 31 (60) INA
Forced expiratory volume in 1 second (%) 79 (72–93) INA
Table 1. Demographic and clinical characteristics of study participants. Data are presented as no. (%) or 
median (interquartile range). NTM-PD, nontuberculous mycobacterial pulmonary disease; INA, information 
not available.
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each), and three healthy individuals were examined by Illumina small RNA sequencing in the discovery phase. 
Averages of 11,217,363 and 18,556,427 reads of RNAs ranging from 18 to 30 nucleotides were obtained from 
pooled serum samples of patients with NTM-PD and healthy controls, respectively. The length distribution of 
clean sequences in the reference genome was determined. Length distribution analysis of serum pools from both 
patients with NTM-PD and healthy controls revealed that most reads were in the range of 18–24 nt, which is 
consistent with the common length of miRNAs28,29. The three pools of serum samples contained small RNAs of 
various lengths (Supplementary Fig. S2). Thereafter, bioinformatics analysis was performed to investigate the 
small RNA species and sequencing frequencies.
In serum derived from patients with NTM-PD and healthy controls, multiple and heterogeneous small RNA 
species, including miRNAs, long intergenic noncoding RNA, ribosomal, small nucleolar, and small nuclear RNA 
were identified (Table 2). In serum samples of patients with NTM-PD and healthy controls, miRNAs accounted 
for 39.7% and 44.5%, respectively, of the total amount of small RNAs (sequencing reads), and there was no signif-
icant difference between the two groups. We analyzed all clean reads using mirDeep software to identify known 
and novel miRNAs. In total, 467 and 407 known miRNAs were identified among patients with NTM-PD and 
healthy controls, respectively (Table 2). Novel miRNA precursors were predicted, and an average of 262 miRNAs 
in patients with NTM-PD and 193 miRNAs in healthy controls were identified (Table 2).
In addition, differentially expressed miRNAs were observed in the serum miRNA profiles of patients with 
NTM-PD relative to in healthy controls (Fig. 1). We identified 148 differentially expressed miRNAs based on 
two-fold changes and p-values less than 0.05. Of these 148 miRNAs, 70 miRNAs showed significant differences 
in expression in patients with M. avium-PD, 56 miRNAs in patients with M. intracellulare-PD, 46 miRNAs in 
patients with M. abscessus-PD, and 32 miRNAs in patients with M. massiliense-PD compared to in healthy con-
trols (Supplementary Tables S1–4, Fig. 2a–d). However, only 14 of these miRNAs were differentially expressed in 
all four patient groups, i.e., in PD due to any of the four NTM organisms (M. avium, M. intracellulare, M. absces-
sus, and M. massiliense) (Fig. 2e,f).
Differential expression of miRNAs via qRT-PCR analysis. As the 14 miRNAs with differential expres-
sion in all four patient groups were considered as potential biomarkers, their expression was verified by qRT-PCR 
analysis. In the selection phase, the 14 candidate miRNAs were measured in a separate set of individual serum 
samples from 12 patients with NTM-PD and three healthy controls, i.e., the number of the same subjects used 
for small RNA sequencing. miRNAs with a mean fold-change (NTM-PD/healthy controls) of >2 and p-values < 
0.05 were selected for further analysis. The analysis indicated that five miRNAs (hsa-miR-423-5p, hsa-miR-484, 
hsa-miR-584-5p, hsa-miR-625-3p, and hsa-miR-4732-5p) of the 14 candidates showed significant differences in 
expression between patients with NTM-PD and healthy controls (Fig. 3).
NTM-PD Healthy controls
Total reads 11,217,363 18,556,427
Precursor miRNA reads 3,445 8,444
Mature miRNA reads 7,250,677 5,265,841
No. of known miRNAs 467 407
No. of novel miRNAs 262 193
Distribution of the genome-mapped sequence reads
miRNA 3,517,419 (39.7) 3,083,932 (44.5)
lincRNA 2,397,431 (27.0) 1,655,179 (23.9)
rRNA 10,857 (0.1) 6,326 (0.1)
snoRNA 8,987 (0.1) 5,626 (0.1)
snRNA 25,265 (0.3) 20,821 (0.3)
others 2,924,390 (32.8) 2,164,554 (31.2)
Distribution of genomic repetitive sequences
LINE (sense) 280,607 (27.0) 237,082 (26.4)
LINE (anti sense) 155,079 (14.9) 136,196 (15.2)
LTR (sense) 148,237 (14.3) 134,467 (15.0)
LTR (anti sense) 105,699 (10.2) 108,196 (12.1)
SINE (sense) 124,916 (12.0) 101,246 (11.3)
SINE (anti sense) 118,899 (11.4) 87,079 (9.7)
Retroposon (sense) 39675 (3.8) 39720 (4.4)
Retroposon (anti sense) 64934 (6.3) 52578 (5.9)
others 766 (0.1) 696 (0.1)
Table 2. The number of miRNAs in serum samples from patients with NTM-PD and healthy controls by small 
RNA sequencing analysis. Data are presented as no. (%). NTM-PD, nontuberculous mycobacterial pulmonary 
disease; miRNA, microRNA; lincRNA, long intergenic noncoding RNA; rRNA, ribosomal RNA; snoRNA, 
small nucleolar RNA; snRNA, small nuclear RNA; LINE, long interspersed nuclear element; LTR, long terminal 
repeat; SINE short interspersed nuclear element.
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qRT-PCR-based validation was performed to quantify differences in the expression levels of the five miRNAs 
in samples from 40 healthy controls and 40 patients with NTM-PD (including NTM-PD due to M. avium, M. 
intracellulare, M. abscessus, and M. massiliense; n = 10 each). Apart from hsa-miR-423-5p (p = 0.116), four of 
the five miRNAs, i.e., hsa-miR-484 (p = 0.015), hsa-miR-584-5p (p = 0.001), hsa-miR-625-3p (p = 0.002), and 
Figure 1. Hierarchical clustering of differentially expressed microRNAs in sera of patients with NTM-PD and 
healthy controls. A total of 148 miRNAs were differentially expressed with separate clustering of NTM-PD 
patients and healthy controls. Each row represents the expression of a given gene in each sample, and each 
column represents the expression of each gene in a given sample. Rows and columns are hierarchically clustered. 
Red and Green colors represent up- and downregulation of miRNAs in NTM-PD patients relative to levels in 
healthy controls.
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has-miR-4732-5p (p = 0.014), showed significantly higher serum expression levels in patients with NTM-PD than 
in healthy controls (Fig. 3).
Receiver operating characteristic (ROC) curve analysis of four miRNAs. Using validation data 
obtained from the 40 patients with NTM-PD and 40 healthy controls, ROC curve analysis was performed to deter-
mine how well the selected serum miRNAs could distinguish between the two groups. miR-423-5p (p = 0.116) 
were removed based on p-values > 0.05. ROC curves were constructed to compare the relative expression levels of 
the four miRNAs between the two groups (Table 3, Fig. 4). The areas under the curves (AUC) of has-miR-4732-5p 
for distinguishing NTM-PD from healthy controls was 0.892(p < 0.0001, 95% CI = 0.800–0.952), which was com-
parable to that of hsa-miR-484, 0.741 (p < 0.0001, 95% CI = 0.631–0.833), hsa-miR-584-5p, 0.712 (p < 0.0001, 
95% CI = 0.597–0.810), and hsa-miR-625-3p, 0.773 (p < 0.0001, 95% CI = 0.665–0.860) (Fig. 4a–d). Multivariate 
Figure 2. Volcano plots and Venn diagram of differentially expressed miRNAs in NTM-PD. (a–d) Volcano 
plots representing log2 fold change as a function of –log10 (the adjusted p-value) for miRNA expression in 
NTM-PD versus healthy controls. miRNAs found to be differentially expressed between the NTM-PD patients 
and controls are shown in black and unchanged miRNAs are shown in grey. (a) Mycobacterium avium patients, 
(b) M. intracellulare patients, (c) M. abscessus patients, and (d) M. massiliense patients. (e) Venn diagram 
showing miRNAs significantly expressed in NTM-PD patients versus healthy controls. (f) Histogram of the 14 
miRNAs that were differentially expressed in NTM-PD from all four NTM species. Expression is shown as fold 
change over levels in healthy controls.
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logistic regression analysis in ROC curve was used to identify the optimal combination of four miRNAs to dis-
criminate NTM-PD. The integration of has-miR-4732-5p with hsa-miR-484 and hsa-miR-625-3p (AUC 0.998; 
sensitivity 95%; and specificity 100%) resulted in an improved diagnostic value for NTM-PD (Fig. 4e).
Construction of miRNA-gene networks. To further investigate the putative functions of the candidate 
miRNAs, the TargetScan database (http://targetscan.org) was used to analyze the target mRNAs, and the Database 
for Annotation, Visualization, and Integrated Discovery (http://david.abcc.ncifcrf.gov/) was used to identify 
the biochemical pathways associated with the conserved targets. Figure 5 shows the miRNA-gene network for 
hsa-miR-484, hsa-miR-584-5p, hsa-miR-625-3p, and hsa-miR-4732-5p. These four miRNAs were associated with 
4231, 2268, 2475, and 2242 target mRNAs in the TargetScan database, respectively. Among these genes, 125 genes, 
including nine genes related to TB, were predicted to be targeted by the four miRNAs in common (Fig. 5a–c). For 
example, hsa-miR-484, hsa-miR-584-5p, hsa-miR-625-3p, and hsa-miR-4732-5p all targeted the nuclear factor 
of activated T cells 5 (NFAT5) and Toll-like receptor 4 (TLR4). Hsa-miR-484, hsa-miR-584-5p, and hsa-miR-
4732-5p targeted interleukin 6 (IL-6), and hsa-miR-484 and hsa-miR-625-3p targeted interleukin-17 (IL-17). 
Has-miR-484 targeted CD40 and the CD40 ligand. Hsa-miR-625-3p targeted CD28, a coreceptor that mediates 
T cell activation.
Go analysis and KEGG pathway analysis of target genes. Gene ontology (GO) and the Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathway analysis were applied to further classify the identified 
genes into the functional groups. GO enrichment analyses were performed to classify 125 target genes based on 
biological processes, molecular function, and cellular component (Fig. 6a). In the case of biological processes, the 
genes were classified into forty-six categories, of which the most significant term was regulation of transcription 
and DNA-template (GO: 0006355). Based on cellular components, the genes were classified into ten categories, 
of which the most significant term was mitochondrial lumen (GO: 0005759). Based on molecular function, the 
Figure 3. Validation of selected miRNA expression levels by qRT-PCR in NTM-PD patients. Serum levels of 
the five miRNAs were measured in 40 NTM-PD patients and in 40 healthy controls. Expression levels of the 
miRNAs are normalized to miR-16. (a) has-miR-423-5p, (b) has-miR-484, (c) has-miR-584-5p, (d) has-miR-
625-3p, and (e) has-miR-4732-5p. qRT-PCR, quantitative real-time PCR; HC, healthy controls; NTM-PD, 
nontuberculous mycobacterial pulmonary disease; NS, not significant.
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genes were classified into eleven categories, of which the most significant term was transition metal ion binding 
(GO: 0046914).
KEGG pathway analysis indicated that 125 putative target genes were mainly involved in central carbon 
metabolism in cancer, proteoglycans in cancer, inositol phosphate metabolism, endocytosis, adherent junction, 
Wnt signaling pathway, lysine degradation, glycosaminoglycan biosynthesis, cell cycle, ECM receptor interaction, 
hippo signaling pathway, and fatty acid biosynthesis (Fig. 6b).
Discussion
This study was conducted to compare the expression profiles of circulating serum miRNA from NTM-PD and 
healthy controls. In the discovery phase, 70 miRNAs in patients with M. avium-PD, 56 miRNAs in patients 
with M. intracellulare-PD, 46 miRNAs in patients with M. abscessus-PD, and 32 miRNAs in patients with M. 
massiliense-PD showed significant differences in expression relative to levels in healthy controls. Differential 
expression of 14 of these miRNAs was common to PD caused by any of the four organisms. In the validation 
phase, using qRT-PCR analysis of sera from additional patients and controls, we confirmed that four miRNAs 
(hsa-miR-484, hsa-miR-584-5p, hsa-miR-625-3p, and hsa-miR-4732-5p) of the 14 miRNAs were differen-
tially expressed in patients. We further determined that 125 gene targets were shared by the candidate miRNAs 
and were associated with NTM-PD on TargetScan analysis. The present study is the first to demonstrate that 
hsa-miR-484, hsa-miR-584-5p, hsa-miR-625-3p, and hsa-miR-4732-5p are associated with NTM-PD and are 
potential biomarkers for NTM-PD. This study is valuable because multiple patients with NTM-PD and disease 
due to several NTM organisms were examined.
In the present study, four serum miRNAs (hsa-miR-484, hsa-miR-584-5p, hsa-miR-625-3p, and hsa-miR-
4732-5p) showed increased expression in patients with NTM-PD compared to in healthy controls. Interestingly, 
these four miRNAs were previously implicated in infection with Mycobacterium bovis bacillus Calmette-Guérin 
(BCG) and immune diseases. miR-484 is upregulated in exosomes of BCG-infected macrophages and targets 
mitochondrial cleavage protein 1 to modulate the intermediate metabolic pathway30. Various assays have revealed 
that miR-484 upregulation clearly influences cell migration and cellular proliferative capacity, and miR-484 is 
also tumorigenic, promoting the progression of non-small cell lung cancer31. miR-584 is reportedly upregulated 
in breast cancer cells, enhancing nuclear factor kappa B signaling, and inhibiting TGF-β signaling32. TGF-β has 
several inhibitory effects on T cells, B cells, macrophages, and other cells, and increased TGF-β levels are associ-
ated with protection and/or recovery from autoimmune diseases33. Previous studies reported that miRNA-625-3p 
in the blood facilitated the detection of malignancy in benign lung tumors34, and miRNA-625-3p is reportedly 
upregulated in the urine of pulmonary TB patients and is an excellent diagnostic urinary biomarker35. miR-
4732-3p is associated with breast cancer and stomach cancer and is specifically expressed in exosomes released 
from macrophages after infection with BCG20,36. We hypothesized that differential expression of these miRNAs in 
patients with NTM-PD and healthy controls would result in differences of target mRNA expression; thus, addi-
tional experimental validation is further required.
In the present study, 125 genes were predicted to be targeted by the four miRNAs, including nine genes related 
to M. tuberculosis infection. Our results revealed that various genes associated with the innate immune response, 
cell proliferation, and apoptosis are potential targets of hsa-miR-484, hsa-miR-584-5p, hsa-miR-625-3p, and 
hsa-miR-4732-5p. Our results further showed that NFAT5 is a target gene for all four miRNAs; NFAT5 plays an 
important role in modulating HIV-1 replication by M. tuberculosis during co-infection, by directly interacting 
with the viral promoter37. Hsa-miR-484, hsa-miR-584-5p, and hsa-miR-4732-5p also targeted IL-6, a pleiotropic 
cytokine that plays a central role in host defense38. These results suggest that the four miRNAs play an important 
role in host-pathogen interactions.
miRNA AUC (95% CI) Sensitivity,% Specificity,%
has-miR-484 0.741 (0.631–0.833) 80.0 70.0
has-miR-584-5p 0.712 (0.597–0.810) 75.0 66.7
has-miR-625-3p 0.773 (0.665–0.860) 60.0 89.7
has-miR-4732-5p 0.892 (0.800–0.952) 80.0 91.7
has-miR-4732-5p+ has-miR-484+ has-miR-584-5p+ 
has-miR-625-3p 0.894 (0.802–0.953) 95.0 71.4
has-miR-4732-5p+ has-miR-484+ has-miR-584-5p 0.905 (0.813–0.962) 82.5 90.6
has-miR-4732-5p+ has-miR-484+ has-miR-625-3p 0.998 (0.949–1.000) 95.0 100.0
has-miR-4732-5p+ has-miR-584-5p+ has-miR-625-3p 0.995 (0.941–1.000) 97.5 96.9
has-miR-4732-5p+ has-miR-484 0.908 (0.819–0.962) 87.5 86.1
has-miR-4732-5p+ has-miR-584-5p 0.888 (0.791–0.950) 80.0 90.6
has-miR-4732-5p+ has-miR-625-3p 0.996 (0.945–1.000) 97.5 97.2
has-miR-484+ has-miR-584-5p 0.776 (0.666–0.863) 80.0 69.4
has-miR-484+ has-miR-625-3p 0.810 (0.706–0.890) 65.0 87.2
has-miR-584-5p+ has-miR-625-3p 0.867 (0.769–0.935) 92.5 74.3
Table 3. Comparison of the AUC, the sensitivity, and specificity for predicting NTM-PD. AUC, area under the 
curve; NTM-PD, nontuberculous mycobacterial pulmonary disease; miRNA, microRNA.
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We performed comprehensive GO enrichment and KEGG pathway analysis of the target genes of the dif-
ferentially expressed miRNAs. GO analysis indicated that these genes are involved in immune responses and 
oxidation-reduction processes and in the regulation of tumor necrosis factor-α. KEGG analysis revealed the 
involvement of these genes in cell growth, migration, and proliferation and in pathways such as Hippo signa-
ling, Wnt signaling, p53 signaling, and TGF-β signaling. Thus, these miRNAs may influence NTM infection, 
as they affect immune cell development. In addition, most proteins encoded by the target genes are involved in 
mitogen-activated protein kinase signaling, Wnt signaling, and TGF-β signaling in NTM-PD and may be useful 
in elucidating the pathogenesis of NTM-PD.
To further evaluate the diagnostic value of hsa-miR-484, hsa-miR-584-5p, hsa-miR-625-3p, and hsa-miR-
4732-5p, we performed a more detailed analysis using ROC curves. The present study found that the ROC curve 
of the combined four differentially expressed miRNAs showed an optimal discriminative ability with an AUC of 
0.998 (95% CI = 0.949–1.000), and diagnostic sensitivity and specificity of 95 and 100%, respectively. Our data 
showed that the diagnostic value of these four miRNAs combination was higher than that of the individual miR-
NAs, indicating that the combinational signature of these four miRNA could serve as discriminating markers for 
NTM-PD.
There are several limitations to the current study. First, the number of samples in this study was small. Second, 
the present study did not include patient subjects with other lung diseases as controls for NTM-PD. To further 
validate the four miRNAs in discriminating NTM-PD from other lung diseases, appropriate PD control groups 
are required to confirm whether our findings are unique to NTM-PD. Finally, the combination sets of miRNAs 
target prediction were solely based on TargetScan database. Thus, the use of efficient genetic algorithms for varia-
ble selection in logistic regression model, rather than a linear model, may have advantages to select the clinically 
optimal markers among all extracted data sets, more accurately39.
In conclusion, to our best knowledge, this is the first study to determine the serum miRNA profiles in 
NTM-PD through deep sequencing. We identified 14 differentially expressed miRNAs in patients with NTM-PD 
compared to in healthy individuals, including nine upregulated miRNAs and five downregulated miRNAs. The 
present study verified the relative expression levels of hsa-miR-484, hsa-miR-584-5p, hsa-miR-625-3p, and 
hsa-miR-4732-5p, indicating their potential as biomarkers for NTM-PD. GO enrichment and KEGG analysis 
showed that the target genes of the four differentially expressed miRNAs were mainly involved in the immune 
response. These results indicate the presence of a serum-specific miRNA signature in patients with NTM-PD, 
which may modulate host antibacterial pathways in response to NTM infection and can be considered a potential 
molecular tool for diagnosing NTM-PD.
Figure 4. Receiver operating characteristic (ROC) curves of four selected miRNAs in NTM-PD patients. 
The ROC curves were used to show the discriminative ability of the selected four miRNAs with sensitivity 
(true-positive rate) and 1-specificity (false-positive rate). The x-axis shows 1-specificity, and the y-axis shows 
sensitivity. Multivariate logistic regression analysis was performed, and ROC curves were generated to evaluate 
the ability of the chosen miRNAs to distinguish NTM-PD patients from controls. (a) has-miR-484, (b) has-miR-
584-5p, (c) has-miR-625-3p, (d) has-miR-4732-5p, and (e) has-miR-panel. AUC, area under the curve; Panel 
1, has-miR-484+ has-miR-584-5p+ has-miR-625-3p+ has-miR-4732-5p; Panel 2, has-miR-484+ has-miR-
584-5p+ has-miR-4732-5p; Panel 3, has-miR-484+ has-miR-625-3p+ has-miR-4732-5p; Panel 4, has-miR-
584-5p+ has-miR-625-3p+ has-miR-4732-5p.
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Figure 5. The miRNA-gene network for miRNAs associated with genes related to NTM-PD. (a) Venn diagram 
showing overlap of gene targets of hsa-miR-484, hsa-miR-584-5p, hsa-miR-625-3p, and hsa-miR-4732-5p. 125 
genes were screened to be targeted by the four miRNAs. (b) miRNA-gene network for hsa-miR-484, hsa-miR-
584-5p, hsa-miR-625-3p, and hsa-miR-4732-5p. The network was built using 125 targeted genes and predicted 
interactions from the TargetScan databases. Red represents miRNAs, and green represents genes; their 
relationship is represented by the edges. (c) Protein-protein interaction analysis performed using the Search 
Tool for the Retrieval of Interacting Genes database revealed that the target genes of hsa-miR-484, hsa-miR-
584-5p, hsa-miR-625-3p, and hsa-miR-4732-5p may interact with each other. The disconnected nodules are 
hidden. Bold lines indicate stronger association.
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Materials and Methods
Study population. Patients with newly diagnosed NTM-PD and who had sera stored at the time of diagno-
sis of NTM-PD were screened from the NTM Registry of Samsung Medical Center, a 1,979-bed referral hospi-
tal in Seoul, South Korea (ClinicalTrials.gov identifier: NCT00970801). To identify NTM-PD-specific miRNAs, 
we excluded patients with diseases that may influence miRNA expression such as chronic medical disease or 
malignancy40. Finally, 52 patients with NTM-PD (13 each with M. avium, M. intracellulare, M. abscessus, and 
M. massiliense infection) were selected and met the diagnostic criteria for NTM-PD41. As healthy controls, 43 
hospital employees with no comorbidities were selected. Sera from the study subjects were separated by centrifu-
gation and stored at −80 °C for subsequent analysis. Patient recruitment and informed consent were carried out 
in accordance with approved guidelines from the Institutional Review Board of Samsung Medical Center (IRB 
No. SMC-2008-09-016).
This study was performed in several phases to identify serum miRNAs that may be useful as markers of 
NTM-PD (Supplementary Fig. S3). Initially, in the discovery phase, screening was conducted by Illumina small 
RNA sequencing to select miRNAs with expression patterns that differed between patients with NTM-PD and 
control subjects. In this step, 15 serum samples were tested to obtain miRNA profiles, with the sera including 
three samples from patients with NTM for each of the four different pathogens, for a total of 12 patient samples, 
as well as three samples from control subjects. A panel of miRNAs showing differential expression in patients 
with NTM-PD and common to PD caused by all four pathogens was subjected to further testing by quantitative 
reverse-transcription (RT)-polymerase chain reaction (PCR) analysis using sera from additional patients and 
control subjects.
RnA extraction. Total RNA was isolated from sera using a miRNeasy Mini Kit (Qiagen, Hilden, Germany) 
following the manufacturer’s protocol. Each sample was eluted in RNase-free water. RNA quantity and purity 
were measured using a NanoDrop™ ND-2000 (Thermo Fisher Scientific, Waltham, MA, USA), and RNA integ-
rity was assessed using an Agilent Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA). The RNA 
samples were stored at −80 °C until further analysis.
Illumina high-throughput sequencing. Small RNA libraries were constructed using the NEXTFlex Small 
RNA Library Prep Kit (Illumina, San Diego, CA, USA) according to the manufacturer’s instructions. Briefly, 
an RNA sequencing library was prepared by cDNA amplification, end-repair, adenylylation of 3′ ends, adapter 
ligation, and amplification. The libraries were sequenced using the HiSeq 2500 system (Illumina) as 50-base pair 
single reads.
Small RNA sequencing data analysis. The read data were assessed and pre-processed using FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc), and low-quality bases were trimmed from the 3′ 
end. Adapter sequences were trimmed and reads shorter than 17 nucleotides were discarded. Trimmed reads 
were mapped to the reference genome (GRCH38/hg19) using Bowtie42. The distribution of mapped reads was 
analyzed by crosschecking with miRBase (http://www.mirbase.org/), Ensembl annotations, and the Rfam data-
base (http://rfam.xfam.org/). Finally, the miRDeep2 program43 (https://www.mdc-berlin.de/content/mird-
eep2-documentation) was used to identify known miRNAs (based on miRNA data from miRBase v20) to predict 
novel miRNAs and summarize the read counts for each miRNA in every sample. Differentially expressed miRNAs 
Figure 6. GO enrichment and KEGG pathway analysis for the target genes of selected miRNAs in NTM-PD. 
(a) GO analysis of hsa-miR-484, hsa-miR-584-5p, hsa-miR-625-3p, and hsa-miR-4732-5p target genes; the 
x-axis indicates -log10(p-value), and the y-axis indicates GO terms; GO, gene ontology; BP, biological processes 
(black); CC, cellular component (dark gray); MF, molecular function (light gray). (b) KEGG pathway analysis 
of hsa-miR-484, hsa-miR-584-5p, hsa-miR-625-3p, and hsa-miR-4732-5p target genes; the x-axis indicates 
-log10(p-value), and the y-axis indicates KEGG pathway categories.
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were identified with a threshold fold-change greater than two and adjusted p-value < 0.05. p-values were calcu-
lated with the DESeq algorithm in the R package for experiments with biological replicates44.
Quantification of miRNAs by qRT-PCR. Reverse transcription reactions were performed using a 
Taq-Man miRNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA) and miRNA-specific 
stem-loop primers in accordance with the manufacturer’s instructions. Each reaction mixture for qRT-PCR 
contained 2.5 μL of 2 × TaqMan Universal PCR Master Mix without AmpErase UNG, 0.25 μL miRNA-specific 
primer/probe mix, and 2.25 μL diluted RT product (1:15) in a total volume of 5 μL. Reactions were carried out 
using the following thermal cycling parameters: 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s, and 60 °C 
for 1 min, followed by holding at 4 °C. Raw data were analyzed using SDS Relative Quantification Software version 
2.2.3 (Applied Biosystems), generally using the automatic Ct setting for assigning baseline and threshold values 
for Ct determination. The expression level of each target miRNA was normalized to that of miR-16 (internal 
control).
miRNA-gene network construction. TargetScan (http://genes.mit.edu/targetscan/index.html) was 
used to predict genes targeted by the obtained miRNAs. Target genes associated with NTM-PD were screened 
using the NCBI database (http://www.ncbi.nlm.nih.gov/pubmed/) and Cytoscape (Cytoscape Software, Version 
2.8.2, Seattle, WA, USA). The miRNA gene network was constructed using Cytoscape to analyze miRNA-mRNA 
interactions.
GO analysis and KEGG pathway analysis. GO enrichment was performed for analysis of the biological 
process, cellular component, and molecular function of target genes based on the GO database (http://www.
geneontology.org/). KEGG pathway analysis was performed to identify the enriched pathways of target genes 
based on the KEGG database (http://www.genome.jp/kegg/). In addition, KEGG pathway annotation of target 
genes was found using data from the Database for Annotation, Visualization and Integrated Discovery (DAVID) 
(http://david.abcc.ncifcrf.gov/).
Statistical analysis. Data are presented as the number (%) for categorical variables and median (interquar-
tile range) for continuous variables. The data were statistically analyzed using SPSS software, version 17.0 (SPSS, 
Inc., Chicago, IL, USA) or the programs built into the software. Briefly, two-tailed unpaired t-tests were per-
formed for one between-group comparison, and one-way analysis of variance was performed for multiple-group 
comparisons. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the discrim-
inative factor of the miRNAs. The AUC with 95% confidence interval (CI) were calculated to determine the 
specificity and sensitivity of discriminative markers of NTM-PD. ROC curve and logistic regression model were 
calculated by using the MedCalc Software (Version 19.1.13, Belgium). A default p < 0.05 was considered statisti-
cally significant.
Data availability
All data generated or analysed during this study are included in this published article and its Supplementary 
Information Files.
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